Benzinga | Feb 25, 2021 11:17AM EST

Mizuho Maintains Buy on Fate Therapeutics, Raises Price Target to $109

Mizuho analyst Mara Goldstein maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $88 to $109.